Division of Emergent BioSolutions Inc.
Latest From Cangene Corp.
US FDA’s Medical Countermeasures Initiative authorities like emergency use authorization have not yet had much of an impact on drugs and biologics, but agency is committed to supporting a swift response to the new strain of coronavirus.
The pace of pharma dealmaking continued unabated in 2015, climaxing with Pfizer’s agreed $160 billion merger with Allergan. Conditions are right for this situation to persist, at least for the foreseeable future.
Twelve novel biologics in 2015 sets record, with 'biobetter' coagulation factors again making up largest group of new products.
The latest drug development news and highlights from our FDA Performance Tracker.
- Specialty Pharmaceuticals
- Therapeutic Areas
- Immune Disorders
- Infectious & Viral Diseases
- North America
- Parent & Subsidiaries
- Emergent BioSolutions Inc.
- Senior Management
John A Sedor, Pres. & CEO
Jeff Lamothe, CFO
Laura Saward, PhD, CSO
Chris Sinclair, VP, Bus. Dev. & Corp. Strategic Planning
Michael Adelman, VP, Commercial Operations
- Contact Info
Phone: (204) 275-4200
155 Innovation Dr.
Winnipeg, R3T 5Y3
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.